The director of Accelerate Diagnostics, Inc. (NASDAQ:AXDX), Jack Schuler Bought 65,000 Shares of the Company

May 17, 2018 - By Kristen Paramore

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Logo

Jack Schuler Insider Buy

An insider of the company Accelerate Diagnostics Inc, Jack Schuler also its director, disclosed his well-informed investment activities with the SEC on 16/05/2018. As discovered in the document, Jack had purchased 65,000 shares of the corporation . The total insider purchase was worth $1.30 million U.S Dollars. At the time of the purchase the price of a share was $20.0. In the last 30 days, he also acquired 100,000 shares with a total value $1.93 million USD. Today, Jack Schuler owns a total of 689,355 shares or 10%+ of the Company’s total market capitalization. It is an important purchase and hence it will possibly not stay disregarded.

Investors sentiment decreased to 0.81 in Q4 2017. Its down 0.82, from 1.63 in 2017Q3. It fall, as 21 investors sold Accelerate Diagnostics, Inc. shares while 32 reduced holdings. 15 funds opened positions while 28 raised stakes. 19.90 million shares or 6.66% less from 21.32 million shares in 2017Q3 were reported.

Selkirk Mgmt Lc holds 361,550 shares. Birchview Cap L P invested in 33.54% or 2.18 million shares. Tci Wealth Advsrs Inc has invested 0.01% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Schwab Charles Invest Mngmt Incorporated has 128,814 shares for 0% of their portfolio. Jpmorgan Chase And has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Parallax Volatility Advisers Limited Partnership owns 3,990 shares. Chartist Ca reported 64,765 shares. Northern Trust has 332,923 shares for 0% of their portfolio. Thompson Investment reported 28,200 shares or 0.13% of all its holdings. Alliancebernstein Ltd Partnership accumulated 32,610 shares. 3,270 were accumulated by Asset One. Principal Fincl Group Inc accumulated 8,294 shares. Ngam Lp holds 0.03% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 121,896 shares. Oaktop Cap Mngmt Ii Limited Partnership has 0.82% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 155,000 shares. Albion Fincl Grp Incorporated Ut invested 0.23% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX).

Since February 20, 2018, it had 7 buys, and 0 selling transactions for $4.73 million activity.

The stock increased 7.71% or $1.55 during the last trading session, reaching $21.65. About 495,767 shares traded or 115.01% up from the average. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has declined 0.88% since May 17, 2017 and is downtrending. It has underperformed by 12.43% the S&P500.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The company has market cap of $1.17 billion. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. It currently has negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

Analysts await Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to report earnings on August, 2. They expect $-0.37 earnings per share, down 19.35 % or $0.06 from last year’s $-0.31 per share. After $-0.37 actual earnings per share reported by Accelerate Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More recent Accelerate Diagnostics, Inc. (NASDAQ:AXDX) news were published by: which released: “Accelerate Diagnostics to Review First Quarter 2018 Results on May 9th” on April 30, 2018. Also published the news titled: “Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018” on April 21, 2018.‘s news article titled: “Report: Developing Opportunities within US Ecology, Universal Health Realty Income Trust, Accelerate Diagnostics ..” with publication date: May 04, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: